Low-Dose IL-2 Shows Promise for Behçet’s Syndrome
In a groundbreaking development that promises to reshape therapeutic strategies for autoimmune disorders, researchers have unveiled compelling evidence supporting the use of low-dose interleukin-2 (IL-2)...















